NDAINJECTIONINJECTABLEPriority Review
Approved
Feb 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
R-GENE 10 (arginine hydrochloride) by Pfizer is clinical pharmacology intravenous infusion of r-gene 10 often induces a pronounced rise in the plasma level of human growth hormone (hgh) in subjects with intact pituitary function. First approved in 1973.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
R-GENE 10 (arginine hydrochloride) is an intravenous diagnostic agent that stimulates human growth hormone (HGH) release in patients with intact pituitary function. It is used clinically to assess pituitary HGH secretion capacity and has been indicated for Type 2 Diabetes management. L-arginine, the active component, is a naturally occurring amino acid with low toxicity.
LOE Approaching
Product is in late-stage lifecycle with minimal remaining market exclusivity, indicating reduced commercial investment and team downsizing likely underway or planned.
Mechanism of Action
CLINICAL PHARMACOLOGY Intravenous infusion of R-Gene 10 often induces a pronounced rise in the plasma level of human growth hormone (HGH) in subjects with intact pituitary function. This rise is usually diminished or absent in patients with impairment of this function. Expected Plasma Levels of HGH…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
R-GENE 10 offers minimal career advancement potential due to its LOE-approaching lifecycle stage, zero linked job opportunities, and declining clinical relevance. Assignment to this product suggests a supporting or maintenance role rather than a growth-oriented career move, with limited visibility and diminishing team resources.
Worked on R-GENE 10 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.